[go: up one dir, main page]

MX9703032A - Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo. - Google Patents

Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.

Info

Publication number
MX9703032A
MX9703032A MX9703032A MX9703032A MX9703032A MX 9703032 A MX9703032 A MX 9703032A MX 9703032 A MX9703032 A MX 9703032A MX 9703032 A MX9703032 A MX 9703032A MX 9703032 A MX9703032 A MX 9703032A
Authority
MX
Mexico
Prior art keywords
benzisothiazolyl
dihydropyridine
ethoxycarbonyl
trimethyl
dioxide
Prior art date
Application number
MX9703032A
Other languages
English (en)
Inventor
Carlos Sunkel Letelier
Francisco Javier Ciller Corral
Miguel Fau De Casajuana Munoz
Pilar Ortega Navarrete
Jaime Priego Fernandez D Campo
Luis Santos Gil
Original Assignee
Alter Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alter Lab filed Critical Alter Lab
Publication of MX9703032A publication Critical patent/MX9703032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Comprende principalmente la aplicacion de este producto como agente terapéutico de aplicacion para el tratamiento de pacientes con aterosclerosis y/o re-estenosis que padecen un riesgo grave de oclulsion de los vasos afectados por la enfermedad. Dicho producto puede administrarse por vía oral o parenteral, asociado o no a otros fármacos, a los pacientes con enfermedad aterosclerotica para reducir la lesion ateromatosa así como para prevenir la re-estenosis de los vasos sanguíneos.
MX9703032A 1995-08-25 1996-08-20 Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo. MX9703032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95500122A EP0771560A1 (en) 1995-08-25 1995-08-25 Use of 2- N-(1,2-benzoisothiazolyl-3(2H)one-1,1-dioxide ethyl 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropiridine-3-carboxylate in the treatment of vascular disorders
PCT/ES1996/000160 WO1997007801A1 (es) 1995-08-25 1996-08-20 Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxilato de 2-[n-(1,2-benzisotiazolil-3(2h)ona-1,1-dioxido]etilo

Publications (1)

Publication Number Publication Date
MX9703032A true MX9703032A (es) 1997-12-31

Family

ID=8221657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9703032A MX9703032A (es) 1995-08-25 1996-08-20 Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.

Country Status (12)

Country Link
EP (1) EP0771560A1 (es)
JP (1) JPH10508879A (es)
KR (1) KR970706817A (es)
AU (1) AU6931496A (es)
BR (1) BR9606691A (es)
CA (1) CA2203624A1 (es)
EA (1) EA199700053A1 (es)
HU (1) HUP9701695A3 (es)
IL (1) IL120718A0 (es)
MX (1) MX9703032A (es)
WO (1) WO1997007801A1 (es)
ZA (1) ZA967223B (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617976A1 (de) * 1986-05-28 1988-01-14 Alter Sa 1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten

Also Published As

Publication number Publication date
EP0771560A1 (en) 1997-05-07
BR9606691A (pt) 2000-05-09
EA199700053A1 (ru) 1997-12-30
HUP9701695A3 (en) 1999-10-28
HUP9701695A2 (hu) 1998-03-30
ZA967223B (en) 1997-03-03
AU6931496A (en) 1997-03-19
IL120718A0 (en) 1997-08-14
WO1997007801A1 (es) 1997-03-06
KR970706817A (ko) 1997-12-01
CA2203624A1 (en) 1997-03-06
JPH10508879A (ja) 1998-09-02

Similar Documents

Publication Publication Date Title
DE3668892D1 (en) Hypoglycemische thiazolidinedione.
EP1040830A4 (en) REMEDY FOR NEURODEGENERATIVE DISEASES
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
AU4069095A (en) Medicaments for the treatment of restenosis and arterial sclerosis
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ATE74271T1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
LT97135A (en) Use of melatonin in the manufacture of a medicament for treating patients suffering from drug addiction
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
AU1458495A (en) Application of riluzole in the treatment of mitochondrial diseases
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
MX9703032A (es) Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP0687687A3 (de) Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
SE9000207L (sv) Laekemedel samt anvaendningen av detsamma
WO1986006960A3 (en) Use of nicorandil or pinacidil for the treatment of peripheral vascular disease
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
AU5903690A (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e) azepine-6, 11-dione and derivatives as drugs for use in the treatment of urinary incontinence
AU8195091A (en) Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease
AU3651595A (en) Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases
EP0987022A4 (en) PREVENTIVE AND HEALING MEDICINES FOR ULCERATIVE KOLITIS AND / OR MORBUS CROHN
AU4016189A (en) Use of 2-azabicyclo(2.2.2) octane-3-carboxylic acid derivatives for the production of medicinal products intended for the treatment of diseases resulting from impairment of the vascular wall as well as for disorders of the microcirculation